Gelonghui, November 28th | Betta Pharmaceuticals (300558.SZ) announced that on November 28, 2024, according to the notification issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2024)" [Healthcare Security Notice [2024] No. 33], the product of Betta Pharmaceuticals, Betafenitin capsule (Simena, hereinafter referred to as "Betafenitin"), is included in the first-line treatment indications in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2024)".

Betafenitin is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), a brand-new national Class 1 innovative drug with independent intellectual property rights. This inclusion for the first-line treatment indications was approved for marketing in October 2023.

The company's products, hydrochloride Aketinib tablets (Kaimena), hydrochloride Ensatinib capsules (Beimina), and Voronib tablets (Fumeina?), all belong to the negotiated drugs within the national healthcare insurance catalog agreement period. Meanwhile, the company's product, Bevacizumab injection (Beanting), remains in the national category B drugs list for healthcare insurance.